Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention

Christopher W. Woods, Cheryl McRill, Brian D. Plikaytis, Nancy E. Rosenstein, David Mosley, Denise Boyd, Bob England, Bradley A. Perkins, Neil M. Ampel, Rana A. Hajjeh

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

From 1 January 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV) infected persons were identified in Arizona (incidence, 41/1000 persons living with AIDS). A case-control study was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons. A case was defined as laboratory- confirmed, incident coccidioidomycosis in a person infected with HIV for ≥3 months, and each case patient had 3 control patients matched by county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count. Multivariable analysis identified black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was associated with a reduced risk. In persons with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug was associated with a reduced risk (odds ratio, 0.4; 95% confidence interval, 0.2-0.9; P = .04). Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in areas of endemicity, have CD4 cell counts <200/μL, are black, or have a history of thrush.

Original languageEnglish (US)
Pages (from-to)1428-1434
Number of pages7
JournalJournal of Infectious Diseases
Volume181
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Coccidioidomycosis
HIV
Incidence
Azoles
Candidiasis
CD4 Lymphocyte Count
Acquired Immunodeficiency Syndrome
Odds Ratio
Oral Candidiasis
Chemoprevention
Protease Inhibitors
Case-Control Studies
Age Groups
Confidence Intervals
Physicians
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Woods, C. W., McRill, C., Plikaytis, B. D., Rosenstein, N. E., Mosley, D., Boyd, D., ... Hajjeh, R. A. (2000). Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention. Journal of Infectious Diseases, 181(4), 1428-1434. https://doi.org/10.1086/315401

Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997 : Incidence, risk factors, and prevention. / Woods, Christopher W.; McRill, Cheryl; Plikaytis, Brian D.; Rosenstein, Nancy E.; Mosley, David; Boyd, Denise; England, Bob; Perkins, Bradley A.; Ampel, Neil M.; Hajjeh, Rana A.

In: Journal of Infectious Diseases, Vol. 181, No. 4, 2000, p. 1428-1434.

Research output: Contribution to journalArticle

Woods, CW, McRill, C, Plikaytis, BD, Rosenstein, NE, Mosley, D, Boyd, D, England, B, Perkins, BA, Ampel, NM & Hajjeh, RA 2000, 'Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention', Journal of Infectious Diseases, vol. 181, no. 4, pp. 1428-1434. https://doi.org/10.1086/315401
Woods, Christopher W. ; McRill, Cheryl ; Plikaytis, Brian D. ; Rosenstein, Nancy E. ; Mosley, David ; Boyd, Denise ; England, Bob ; Perkins, Bradley A. ; Ampel, Neil M. ; Hajjeh, Rana A. / Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997 : Incidence, risk factors, and prevention. In: Journal of Infectious Diseases. 2000 ; Vol. 181, No. 4. pp. 1428-1434.
@article{5f0d66180e6a4c8aa4efadfa8976225c,
title = "Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention",
abstract = "From 1 January 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV) infected persons were identified in Arizona (incidence, 41/1000 persons living with AIDS). A case-control study was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons. A case was defined as laboratory- confirmed, incident coccidioidomycosis in a person infected with HIV for ≥3 months, and each case patient had 3 control patients matched by county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count. Multivariable analysis identified black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was associated with a reduced risk. In persons with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug was associated with a reduced risk (odds ratio, 0.4; 95{\%} confidence interval, 0.2-0.9; P = .04). Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in areas of endemicity, have CD4 cell counts <200/μL, are black, or have a history of thrush.",
author = "Woods, {Christopher W.} and Cheryl McRill and Plikaytis, {Brian D.} and Rosenstein, {Nancy E.} and David Mosley and Denise Boyd and Bob England and Perkins, {Bradley A.} and Ampel, {Neil M.} and Hajjeh, {Rana A.}",
year = "2000",
doi = "10.1086/315401",
language = "English (US)",
volume = "181",
pages = "1428--1434",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997

T2 - Incidence, risk factors, and prevention

AU - Woods, Christopher W.

AU - McRill, Cheryl

AU - Plikaytis, Brian D.

AU - Rosenstein, Nancy E.

AU - Mosley, David

AU - Boyd, Denise

AU - England, Bob

AU - Perkins, Bradley A.

AU - Ampel, Neil M.

AU - Hajjeh, Rana A.

PY - 2000

Y1 - 2000

N2 - From 1 January 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV) infected persons were identified in Arizona (incidence, 41/1000 persons living with AIDS). A case-control study was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons. A case was defined as laboratory- confirmed, incident coccidioidomycosis in a person infected with HIV for ≥3 months, and each case patient had 3 control patients matched by county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count. Multivariable analysis identified black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was associated with a reduced risk. In persons with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug was associated with a reduced risk (odds ratio, 0.4; 95% confidence interval, 0.2-0.9; P = .04). Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in areas of endemicity, have CD4 cell counts <200/μL, are black, or have a history of thrush.

AB - From 1 January 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV) infected persons were identified in Arizona (incidence, 41/1000 persons living with AIDS). A case-control study was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons. A case was defined as laboratory- confirmed, incident coccidioidomycosis in a person infected with HIV for ≥3 months, and each case patient had 3 control patients matched by county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count. Multivariable analysis identified black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was associated with a reduced risk. In persons with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug was associated with a reduced risk (odds ratio, 0.4; 95% confidence interval, 0.2-0.9; P = .04). Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in areas of endemicity, have CD4 cell counts <200/μL, are black, or have a history of thrush.

UR - http://www.scopus.com/inward/record.url?scp=0034105276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034105276&partnerID=8YFLogxK

U2 - 10.1086/315401

DO - 10.1086/315401

M3 - Article

C2 - 10753734

AN - SCOPUS:0034105276

VL - 181

SP - 1428

EP - 1434

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -